Nitazoxanide - Genfit
Alternative Names: G 1090N; NTZ - Genfit; Repurposed nitazoxanide - GenfitLatest Information Update: 17 Feb 2025
At a glance
- Originator Genfit
- Developer Genfit; Pinnacle Clinical Research
- Class Amides; Anthelmintics; Anti-inflammatories; Antidiarrhoeals; Antifibrotics; Antiprotozoals; Antivirals; Benzamides; Hepatoprotectants; Nitro compounds; Phenylacetates; Small molecules; Thiazoles
- Mechanism of Action EIF-2 kinase modulators; HN protein inhibitors; Oxidoreductase inhibitors; Receptor protein-tyrosine kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Hepatic fibrosis
- No development reported Liver failure
Most Recent Events
- 06 Feb 2025 Genfit plans a clinical trial for Liver failure in the first quarter of 2025
- 28 Dec 2024 No recent reports of development identified for phase-I development in Liver-failure in USA (PO)
- 21 Jun 2023 Pharmacodynamics data from a preclinical studies in acute-on-chronic liver failure presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)